MEI Pharma Inc MEIP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/03/24 EDT
3.06UNCH (UNCH)
Volume
16,997
52 week range
3.01 - 6.91
Loading...
  • Open3.13
  • Day High3.18
  • Day Low3.06
  • Prev Close3.06
  • 52 Week High6.91
  • 52 Week High Date12/07/23
  • 52 Week Low3.01
  • 52 Week Low Date05/01/24

Key Stats

  • Market Cap20.388M
  • Shares Out6.66M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change-47.24

KEY STATS

  • Open3.13
  • Day High3.18
  • Day Low3.06
  • Prev Close3.06
  • 52 Week High6.91
  • 52 Week High Date12/07/23
  • 52 Week Low3.01
  • 52 Week Low Date05/01/24
  • Market Cap20.388M
  • Shares Out6.66M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change-47.24

RATIOS/PROFITABILITY

  • EPS (TTM)2.98
  • P/E (TTM)1.03
  • Fwd P/E (NTM)-0.98
  • EBITDA (TTM)16.247M
  • ROE (TTM)36.80%
  • Revenue (TTM)72.648M
  • Gross Margin (TTM)19.42%
  • Net Margin (TTM)27.32%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date11/16/2023
  • Div Amount1.75
  • Split Date-
  • Split Factor-

Latest On MEI Pharma Inc

 

Profile

MORE
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial...
Charles Baltic III
Independent Chairman of the Board
David Urso J.D.
President, Chief Executive Officer, Director
Justin File
Chief Financial Officer, Corporate Secretary
Address
11455 El Camino Real, Suite 250
San Diego, CA
92130
United States

Top Peers

SYMBOLLASTCHG%CHG
AYTU
Aytu Biopharma Inc
3.01UNCHUNCH
OPTN
OptiNose Inc
1.01+0.13+15.09%
CPIX
Cumberland Pharmaceuticals Inc
1.58+0.07+4.64%
BFRI
Biofrontera Inc
1.72-0.07-3.91%
CASI
CASI Pharmaceuticals Inc
2.89+0.21+7.84%